PPIs and H2RAs have same impact on mortality, finds study
Canada: PPIs and H2RAs more or less have a similar effect on mortality compared to no treatment, suggests a recent study in the journal Intensive Care Medicine. However, based on low certainty evidence the possibility of slightly increased mortality associated with PPI use cannot be excluded.
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) use help to achieve reductions in gastrointestinal bleeding. The greater benefit of PPIs over H2RAs may be important for patients with higher bleeding risk.
Based on findings from the PEPTIC trial that has raised the issue of increased mortality with PPI use over H2RAs, Ying Wang, McMaster University, Hamilton, Canada, and colleagues updated their prior systematic review and network meta-analysis (NMA) that addressed the impact of pharmacological gastrointestinal bleeding prophylaxis in critically ill patients.
The researchers searched for randomized controlled trials that examined the safety and efficacy of gastrointestinal bleeding treatment with PPIs, H2RAs, or sucralfate versus one another or placebo or no prophylaxis in adult critically ill patients. They performed Bayesian random-effects NMA and conducted analyses using all PEPTIC data. Also, they performed a restricted analysis using only PEPTIC data from high compliance centers. The GRADE approach was used to quantify absolute effects and assess the certainty of evidence.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.